News Category
In vitro ADME studies are critical for early assessment of drug candidates, helping to avoid costly clinical trial failures and accelerate development...
GeoVax's next-generation MVA-X vaccine achieved durable single-dose protection against highly pathogenic Clade I mpox and other orthopoxviruses in pre...
Onco-Innovations is integrating manufacturing, preclinical, and regulatory activities for its lead cancer candidate ONC010, aiming to initiate first-i...
VERAXA Biotech has named Raju Willener as CFO, bringing over 30 years of capital markets experience to support the company's BiTAC oncology platform a...
Apimeds Pharmaceuticals US, Inc. has engaged IBN to enhance its corporate communications, aiming to increase investor awareness of its subsidiary Mind...
Regentis Biomaterials is advancing its GelrinC cartilage repair product through a U.S. pivotal trial and European commercialization, targeting a signi...
Silo Pharma's U.S. patent allowance for SPC-15 strengthens its intellectual property position in developing a novel intranasal treatment for PTSD, a c...
Regentis Biomaterials has moved its GelrinC hydrogel implant into a pivotal stage of development, potentially offering the first off-the-shelf solutio...
New research suggests that accelerated biological aging could be behind the increasing incidence of cancer in adults under 55, prompting further inves...
VERAXA Biotech's appointment of Raju Willener as CFO brings over 30 years of capital markets expertise to advance its BiTAC oncology pipeline, signali...
Regentis Biomaterials is advancing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, with European approval and an FDA...
Med-X is expanding its Nature-Cide natural pest-control brand and securing key certifications as it prepares for a Nasdaq debut, signaling potential g...
Telomir Pharmaceuticals' Telomir-Zn demonstrated growth inhibition in human and canine osteosarcoma cell lines at similar low concentrations, supporti...
Quantum BioPharma has received FDA clearance for its Investigational New Drug application for Lucid-MS, enabling a Phase 2 trial in multiple sclerosis...
GeoVax's agreement with CEPI to use its centralized laboratory network for the Phase 3 trial of GEO-MVA could provide independent validation of the va...
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNAs can restore full-length dystrophin and improve muscle...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities to help researchers engineer precise delivery pl...
Creative Biolabs has expanded its single-cell and single-nucleus RNA sequencing and multi-omics services to help researchers overcome sample processin...
A comprehensive review reveals that the tumor microenvironment actively reshapes natural killer cells into distinct subsets with specialized roles, of...
GeoVax Labs is appealing a Nasdaq delisting determination while continuing to advance its GEO-MVA vaccine and Gedeptin oncology programs, highlighting...
Regentis Biomaterials has treated 43 of 80 patients in its Phase III GelrinC trial, secured a European manufacturing approval that boosts yield by 400...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective drug, has received FDA clearance for a Phase 2 trial that could revolutionize MS trea...
TransCode Therapeutics names John Tattory as interim CFO following Tom Fitzgerald's retirement, bringing extensive financial leadership to support the...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its BiTAC® T-cell engager platform...
Quantum BioPharma receives FDA clearance for its IND application for Lucid-MS, enabling a Phase 2 trial in multiple sclerosis and highlighting the pot...
Quantum BioPharma receives FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis candidate designed to protect and ...
Quantum BioPharma has received FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to protect and r...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting the company's late...
Onco-Innovations' CMO detailed the company's novel PNKP-targeting drug candidate ONC010, which uses synthetic lethality and nanoparticle delivery to p...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial for multiple sclerosis...
American Fusion has advanced its Texatron fusion program into active testing with peak pressures of 100,000 atmospheres, signaling progress toward com...
Kairos Pharma's CEO will present at a major investment conference, underscoring the company's progress in developing ENV-105, a promising antibody des...
Nutriband's CEO participation at the Nasdaq LaB summit underscores the company's growing prominence in abuse-deterrent transdermal technology, potenti...
Silo Pharma's participation in the IPAC-RS forum underscores its progress in developing SPC-15, a nose-to-brain PTSD treatment, with stable preclinica...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial signifies a pivotal step toward a novel therapy that may repair myelin damage in multiple...
Quantum BioPharma’s Lucid-MS, a first-in-class myelin-protective multiple sclerosis drug candidate, has received FDA clearance to begin a Phase 2 tria...
Helus Pharma's CEO participation at a major investment conference underscores the company's advancing clinical pipeline for depression and anxiety, si...
GeoVax supports the new global mpox vaccine stockpile initiative as a step toward sustainable preparedness, highlighting its GEO-MVA candidate's readi...
Voyageur Pharmaceuticals has achieved a key milestone in its collaboration with Bayer, securing $1 million in non-dilutive funding after proving its i...
Greenland Mines announces Q4 biotech spin-off and Nasdaq compliance, while completing the Sarfartoq acquisition with a high-case NPV of $2.05 billion,...
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to strengthen its financial leadership and support the advancement of it...
Scinai Immunotherapeutics has strategically ended its PinCell collaboration to focus on its NanoAb platform and growing CDMO business, aiming to maxim...
Onco-Innovations advances its oncology pipeline with key manufacturing, IND-enabling, and capital developments, positioning ONC010 for clinical transl...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS marks a potential breakthrough in MS treatment by targeting myelin repair, a first f...
OS Animal Health's presentation at the Moody Capital conference highlights its progress toward USDA conditional approval for OST-HER2, a promising imm...
Quantum BioPharma's FDA clearance to test Lucid-MS in phase 2 trials marks a historic step toward a therapy that could repair myelin, addressing an un...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the Pan African Clinical Trials Registry, marking a critical ...
Greenland Mines announces a Q4 2026 biotech spin-off, Nasdaq compliance, and Sarfartoq acquisition, positioning itself as a focused rare earths player...
